Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone Safety in Dialysis Patients
NCT00328809Phase 4Withdrawn
- Sponsor
- Upstate Medical University
- Start
- Jun 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spironolactone in heart failure (HF), sponsored by Upstate Medical University. Primary endpoint: risk of hyperkalemia at 6 months. Planned start Jun 2013; status: withdrawn.
02
Drugs
spironolactone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00328809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00328809.